Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

SGLT2 inhibitors and ophthalmic diseases in elderly patients with diabetes

Impact of SGLT2 inhibitors on the risk of age-related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study.

Diabetes, obesity & metabolism

Citation & Authors

Diabetes Obes Metab. 2025;27(12):7299-7308.

Yueh-Tsung Lee; Jheng-Yan Wu; Tsung W Chang; Cheng-Hsien Hung

ABSTRACT · RESEARCH SUMMARY

Research summary

In a target trial emulation involving patients aged ≥60 years with type 2 diabetes, SGLT2 inhibitors were associated with lower risks of nonexudative macular degeneration (HR 0.64; 95% CI 0.49–0.84) and exudative degeneration than DPP-4 inhibitors, but with a slightly increased risk of cataract (1.08; 1.02–1.15). Atrophic degeneration, ocular hypertension, and glaucoma did not differ significantly.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗